Therefore, deeply understanding the compensatory activation process of HER3 and developing HER2/HER3 co-targeted drugs are of great clinical significance and will provide a new avenue for patients with HER2-positive advanced breast cancer who have failed multiple lines of treatment. This evidence concerns the gene ERBB2 and breast carcinoma.